4-methyl-1,4-diaza-bicyclo[3.2.1]octane | 5167-11-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: 4-methyl-1,4-diaza-bicyclo[3.2.1]octane
• 英文别名: 4-Methyl-1,4-diazabicyclo[3.2.1]octane
• CAS: 5167-11-3
• 化学式: C₇H₁₄N₂
• 分子量: 126.202
• InChiKey: YKBHIAMXELZBES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PURINE UTILES COMME INHIBITEURS DE PI3 KINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009053716A1

  公开（公告）日：2009-04-30

  This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110δ isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases. The compounds may be used to treat diseases and disorders arisi from abnormal cell growth, function or behaviour associated with PI3 kinase such as cance immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

  这项发明提供了一种化合物，其为式(Ia)或(Ib)的嘌呤类化合物：及其药学上可接受的盐，这些化合物是PI3K的抑制剂，并且对p110δ同工型具有选择性，p110δ是Ia类PI3激酶，优于其他Ia类PI3激酶和Ib类激酶。这些化合物可用于治疗由于与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和紊乱，如癌症、免疫紊乱、心血管疾病、病毒感染、炎症、代谢/内分泌功能紊乱和神经系统疾病。
• [EN] CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR<br/>[FR] DÉRIVÉS CONDENSÉS D'AZINE POUR LE TRAITEMENT DE MALADIES LIÉES AUX RÉCEPTEURS DE L'ACÉTYLCHOLINE
  申请人：ORGANON NV

  公开号：WO2011045258A1

  公开（公告）日：2011-04-21

  The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by nicotinic acetylcholine receptors, such as schizophrenia and Alzheimer's disease.

  本发明涉及式(I)的杂环衍生物，其中变量如规范中所定义，或其药用可接受盐或溶剂。本发明还涉及包含所述杂环衍生物的药物组合物，以及它们在治疗中的应用，例如在治疗或预防由尼古丁乙酰胆碱受体介导的疾病，如精神分裂症和阿尔茨海默病。
• Compounds for the Treatment of Hepatitis C
  申请人：Bergstrom Carl P.

  公开号：US20090042860A1

  公开（公告）日：2009-02-12

  The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

  这项发明涵盖了公式I的化合物，以及使用这些化合物的组合物和方法。这些化合物对丙型肝炎病毒（HCV）具有活性，并可用于治疗感染HCV的人。
• [EN] SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES<br/>[FR] INHIBITEURS DE FURINE À PETITES MOLÉCULES POUR LE TRAITEMENT DE MALADIES INFECTIEUSES
  申请人：BP ASSET V INC

  公开号：WO2021097009A1

  公开（公告）日：2021-05-20

  Provided herein are methods of treating a viral infection in a subject in need thereof, comprising administering to the subject a compound of Formula (I), or a pharmaceutical composition comprising Formula (I). Further provided herein are methods for inhibiting the replication of a virus (e.g., a togaviridae family virus (e.g., an alphavirus (e.g., Chikungunya virus, Eastern equine encephalitis, Mayaro virus, Venezuelan equine encephalitis virus, Western equine encephalitis)), a filoviradae family virus (e.g., a Marburg virus (e.g., Marburg virus, Ravn virus)), human respiratory syncytial virus (i.e., human orthopneumo viru s ), a flavivirus (e.g., dengue virus, Usutu virus, Japanese encephalitis virus, Powassan virus, yellow fever), a paramyxoviridae family virus (e.g., an orthoparamyxovirinae virus (e.g., a henipavims (e.g., Nipah virus), a morbillivims (e.g., measles morbillivirus))) in a subject in need thereof. Also provided herein are methods for treating and/or preventing a disorder due to a microbial toxin (e.g., due to P. aeruginosa exotoxin A, Clostridium septicum alpha-toxin, diphtheria toxin(s), shiga toxin(s)) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutical composition comprising a compound of Formula (I) as described herein. Also provided are pharmaceutical compositions and kits including a compound of Formula (I) for use in the treatment and/or prevention of a viral infection in a subject in need thereof.

  本文提供了治疗需要的受试者体内病毒感染的方法，包括向受试者投与化合物I的方法，或者包含化合物I的药物组合物。本文还提供了用于抑制病毒复制的方法（例如togaviridae家族病毒（例如alphavirus（例如，基孔肯雅病毒，东部马脑炎，马雅罗病毒，委内瑞拉马脑炎病毒，西部马脑炎）），filoviradae家族病毒（例如马尔堡病毒（例如，马尔堡病毒，拉文病毒）），人类呼吸道合胞病毒（即人类正交病毒），黄病毒（例如登革病毒，乌苏图病毒，日本脑炎病毒，波瓦松病毒，黄热病），paramyxoviridae家族病毒（例如正参数病毒（例如蝙蝠病毒（例如，尼帕病毒），麻病毒（例如，麻疹麻病毒）））的方法。本文还提供了治疗和/或预防由微生物毒素引起的紊乱的方法（例如由P. aeruginosa外毒素A，肠炎类固醇α-毒素，白喉毒素，志贺毒素引起的紊乱）的方法，包括向受试者投与化合物I的治疗有效量，或者包含本文所述的化合物I的药物组合物。还提供了包含化合物I的药物组合物和配套用品，用于治疗和/或预防需要的受试者体内的病毒感染。
• [EN] USE OF PYRIDYLOXYPYRIDINES FOR TREATING INFECTIOUS DISEASES<br/>[FR] UTILISATION DE PYRIDYLOXYPYRIDINES POUR LE TRAITEMENT DE MALADIES INFECTIEUSES
  申请人：BP ASSET V INC

  公开号：WO2021097008A1

  公开（公告）日：2021-05-20

  Provided herein are methods of treating a viral infection in a subject in need thereof, comprising administering to the subject a compound of Formula (I), or a pharmaceutical composition comprising Formula (I). Further provided herein are methods for inhibiting the replication of a virus (e.g., a togaviridae family virus (e.g., an alphavirus (e.g., Chikungunya virus, Eastern equine encephalitis, Mayaro virus, Venezuelan equine encephalitis virus, Western equine encephalitis)), a filoviradae family virus (e.g., a Marburg virus (e.g., Marburg virus, Ravn virus)), human respiratory syncytial virus (i.e., human orthopneumo viru s ), a flavivirus (e.g., dengue virus, Usutu virus, Japanese encephalitis virus, Powassan virus, yellow fever), a paramyxoviridae family virus (e.g., an orthoparamyxovirinae virus (e.g., a henipavims (e.g., Nipah virus), a morbillivims (e.g., measles morbillivirus))) in a subject in need thereof. Also provided herein are methods for treating and/or preventing a disorder due to a microbial toxin (e.g., due to P. aeruginosa exotoxin A, Clostridium septicum alpha-toxin, diphtheria toxin(s), shiga toxin(s)) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutical composition comprising a compound of Formula (I) as described herein. Also provided are pharmaceutical compositions and kits including a compound of Formula (I) for use in the treatment and/or prevention of a viral infection in a subject in need thereof.

  本文提供了治疗需要的受试者体内病毒感染的方法，包括向受试者施用化合物I的方法，或者包含化合物I的药物组合物。本文还提供了抑制病毒复制的方法（例如togaviridae家族病毒（例如alphavirus（例如基康肯雅病毒、东方马脑炎、马雅罗病毒、委内瑞拉马脑炎病毒、西方马脑炎））、filoviradae家族病毒（例如Marburg病毒（例如马尔堡病毒、拉文病毒））、人类呼吸道合胞病毒（即人类正肺病毒）、黄病毒（例如登革病毒、乌苏图病毒、日本脑炎病毒、波瓦山病毒、黄热病）、paramyxoviridae家族病毒（例如orthoparamyxovirinae病毒（例如蝙蝠病毒（例如尼帕病毒）、麻痹病毒（例如麻疹麻痹病毒）））的复制。本文还提供了治疗和/或预防由微生物毒素引起的疾病的方法（例如由P. aeruginosa外毒素A、肠炎梭菌α-毒素、白喉毒素、志贺毒素引起的疾病），包括向受试者施用化合物I的治疗有效量，或者包含本文所述的化合物I的药物组合物。还提供了包含化合物I的药物组合物和配套用品，用于治疗和/或预防需要的受试者体内的病毒感染。